Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Pediatric Patients With Primary IgAN
NCT06994845Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Nov 2025
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of Iptacopan in IgA nephropathy (IgAN), sponsored by Novartis. Started Nov 2025; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06994845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06994845.